TOP HEADLINES

Featured Story

  • Genocea's genital herpes vaccine succeeds in PhII

    There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.

U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial

Oxford-based PsiOxus closed a Series C financing round, scoring £25 million ($39 million) to advance its lead candidate, enadenotucirev, an oncolytic virus aimed at fighting colorectal tumors. The funding came from GlaxoSmithKline's VC unit and U.K. heavyweight investor Neil Woodford's new $1.2 billion fund.

Zydus Cadila preps for big splash into India's vaccines market

With ambitious plans for the next year, Ahmedabad-based Zydus Cadila's coming launches could alter the vaccines landscape in India and challenge established players there.

NIH steps in with $9M Vanderbilt grant after rough season for flu vaccines

After a troublesome flu vaccine season, the NIH has announced that it'll lend a hand to Vanderbilt University as researchers there attempt to develop an improved, "universal" vaccine against the virus.

Canadian biotech Medicago building $200M vaccine plant

Medicago is building a $200 million manufacturing facility in Quebec City, where it will use plant technology to produce vaccines against Ebola and other viruses.

Ebola news: GSK, Emergent start Phase I trial; Bavarian Nordic scores €50M for vaccine development

In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in part toward its programs in Ebola and infectious diseases.

MORE NEWS

From Our Sister Sites

FierceBiotech

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...

FiercePharma

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.